Opinion: Ending tuberculosis will take continued private-sector innovation
Drugs to treat multidrug-resistant tuberculosis sometimes do as much harm as good. We can do better.
Imagine needing treatment for a life-threatening infectious disease like tuberculosis and the only drug available to you often causes deafness.
That’s what happened to an extraordinary young woman I met in Mumbai, India, earlier this year. In many ways, Prisha (not her real name) is just like many other women in their late 20s: She has a successful career and ambitious dreams for her future. But she is also a two-time survivor of multidrug-resistant tuberculosis (MDR-TB) — a strain of the bacterial infection that does not respond to the most commonly used anti-TB drugs.
During Prisha’s second
